1. Home
  2. GDTC

as of 05-06-2026 11:32am EST

$0.92
+$0.00
+0.01%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Founded: 2018 Country:
Singapore
Singapore
Employees: N/A City: N/A
Market Cap: 12.4M IPO Year: 2021
Target Price: N/A AVG Volume (30 days): 5.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.73 - $3.68 Next Earning Date: 04-24-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: